Vaxil Historical Income Statement

VXL Stock

CAD 0.01 0.00 0.00%

Historical analysis of Vaxil Bio income statement accounts such as Selling General Administrative of 114, Selling And Marketing Expenses of 17.1, Other Operating Expenses of 241 or Cost Of Revenue of 1.7 K can show how well Vaxil Bio performed in making a profits. Evaluating Vaxil Bio income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Vaxil Bio's future profits or losses.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Vaxil Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vaxil Bio is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Vaxil Income Statement Analysis

Vaxil Bio Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Vaxil Bio shareholders. The income statement also shows Vaxil investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Vaxil Bio Income Statement Chart

At this time, Vaxil Bio's Total Other Income Expense Net is fairly stable compared to the past year. Income Tax Expense is likely to climb to about 13.3 K in 2024, whereas Selling And Marketing Expenses is likely to drop 17.10 in 2024.

Selling General Administrative Selling And Marketing Expenses Other Operating Expenses Cost Of Revenue Income Before Tax Net Income

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Vaxil Bio. It is also known as Vaxil Bio overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Vaxil Bio income statement and represents the costs associated with goods and services Vaxil Bio provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Vaxil Bio income statement and is an important metric when analyzing Vaxil Bio profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Vaxil Bio financial statement analysis. It represents the amount of money remaining after all of Vaxil Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most accounts from Vaxil Bio's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Vaxil Bio current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	986K	584K	254.0	241.3
Cost Of Revenue	25K	2K	1.8K	1.7K

Total Operating Expenses Cost Of Revenue

Vaxil Bio income statement Correlations

	Selling General Administrative	Selling And Marketing Expenses	Gross Profit	Other Operating Expenses	Operating Income	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Net Income	Interest Expense	Total Other Income Expense Net	Income Tax Expense	Depreciation And Amortization	Ebit	Net Income From Continuing Ops	Research Development	Net Interest Income	Interest Income	Reconciled Depreciation
Selling General Administrative		-0.14	0.03	0.97	-0.97	-0.97	-0.03	0.97	-0.97	-0.97	-0.01	-0.52	0.69	-0.21	-0.97	-0.04	0.44	0.13	0.24	0.19
Selling And Marketing Expenses	-0.14		-0.24	-0.23	0.23	0.22	0.24	-0.25	0.24	0.24	0.67	0.18	-0.42	-0.34	0.27	-0.8	-0.49	0.4	0.18	0.12
Gross Profit	0.03	-0.24		-0.06	0.06	0.06	-1.0	-0.01	0.06	0.06	-0.59	0.04	-0.07	-0.09	0.01	0.26	-0.12	0.18	-0.22	-0.39
Other Operating Expenses	0.97	-0.23	-0.06		-1.0	-1.0	0.06	1.0	-1.0	-1.0	-0.05	-0.51	0.7	-0.2	-1.0	0.09	0.65	-0.05	0.31	0.29
Operating Income	-0.97	0.23	0.06	-1.0		1.0	-0.06	-1.0	1.0	1.0	0.05	0.51	-0.71	0.2	1.0	-0.08	-0.64	0.05	-0.31	-0.29
Ebitda	-0.97	0.22	0.06	-1.0	1.0		-0.06	-1.0	1.0	1.0	0.06	0.49	-0.69	0.22	1.0	-0.08	-0.63	0.03	-0.31	-0.28
Cost Of Revenue	-0.03	0.24	-1.0	0.06	-0.06	-0.06		0.01	-0.06	-0.06	0.59	-0.04	0.07	0.09	-0.02	-0.26	0.12	-0.18	0.22	0.39
Total Operating Expenses	0.97	-0.25	-0.01	1.0	-1.0	-1.0	0.01		-1.0	-1.0	-0.09	-0.5	0.7	-0.2	-1.0	0.11	0.66	-0.06	0.31	0.28
Income Before Tax	-0.97	0.24	0.06	-1.0	1.0	1.0	-0.06	-1.0		1.0	0.04	0.53	-0.71	0.19	1.0	-0.09	-0.64	0.05	-0.31	-0.29
Net Income	-0.97	0.24	0.06	-1.0	1.0	1.0	-0.06	-1.0	1.0		0.04	0.53	-0.71	0.19	1.0	-0.09	-0.65	0.06	-0.31	-0.29
Interest Expense	-0.01	0.67	-0.59	-0.05	0.05	0.06	0.59	-0.09	0.04	0.04		-0.43	0.07	0.08	0.09	-0.58	-0.26	0.2	0.16	0.16
Total Other Income Expense Net	-0.52	0.18	0.04	-0.51	0.51	0.49	-0.04	-0.5	0.53	0.53	-0.43		-0.72	-0.29	0.51	-0.05	-0.24	0.05	-0.1	-0.16
Income Tax Expense	0.69	-0.42	-0.07	0.7	-0.71	-0.69	0.07	0.7	-0.71	-0.71	0.07	-0.72		0.27	-0.7	0.47	0.43	-0.16	-0.11	-0.07
Depreciation And Amortization	-0.21	-0.34	-0.09	-0.2	0.2	0.22	0.09	-0.2	0.19	0.19	0.08	-0.29	0.27		0.16	0.36	-0.07	-0.35	-0.74	-0.26
Ebit	-0.97	0.27	0.01	-1.0	1.0	1.0	-0.02	-1.0	1.0	1.0	0.09	0.51	-0.7	0.16		-0.1	-0.64	0.05	-0.27	-0.26
Net Income From Continuing Ops	-0.04	-0.8	0.26	0.09	-0.08	-0.08	-0.26	0.11	-0.09	-0.09	-0.58	-0.05	0.47	0.36	-0.1		0.5	-0.53	-0.32	-0.23
Research Development	0.44	-0.49	-0.12	0.65	-0.64	-0.63	0.12	0.66	-0.64	-0.65	-0.26	-0.24	0.43	-0.07	-0.64	0.5		-0.61	0.37	0.44
Net Interest Income	0.13	0.4	0.18	-0.05	0.05	0.03	-0.18	-0.06	0.05	0.06	0.2	0.05	-0.16	-0.35	0.05	-0.53	-0.61		0.02	-0.36
Interest Income	0.24	0.18	-0.22	0.31	-0.31	-0.31	0.22	0.31	-0.31	-0.31	0.16	-0.1	-0.11	-0.74	-0.27	-0.32	0.37	0.02		0.61
Reconciled Depreciation	0.19	0.12	-0.39	0.29	-0.29	-0.28	0.39	0.28	-0.29	-0.29	0.16	-0.16	-0.07	-0.26	-0.26	-0.23	0.44	-0.36	0.61

Click cells to compare fundamentals

Vaxil Bio Account Relationship Matchups

Vaxil Bio income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Selling General Administrative	383K	724K	428K	239K	120.0	114.0
Gross Profit	(100K)	(57K)	(25K)	(2K)	(2.3K)	(2.4K)
Other Operating Expenses	1.1M	1.3M	986K	584K	254.0	241.3
Operating Income	(1.1M)	(1.3M)	(986K)	(584K)	(254.0)	(266.7)
Ebitda	(1.0M)	(1.3M)	(961K)	(582K)	(252.0)	(264.6)
Cost Of Revenue	100K	57K	25K	2K	1.8K	1.7K
Total Operating Expenses	1.1M	1.3M	986K	584K	254.0	241.3
Income Before Tax	(1.2M)	(1.4M)	(986K)	(584K)	(254.0)	(266.7)
Net Income	(1.2M)	(1.4M)	(986K)	(584K)	(254.0)	(266.7)
Depreciation And Amortization	100K	57K	25K	2K	167.9K	176.3K
Ebit	(1.1M)	(1.3M)	(986K)	(584K)	(168.1K)	(176.6K)
Net Income From Continuing Ops	(1.2M)	(1.4M)	(986K)	(584K)	(254K)	(266.7K)
Research Development	750K	619K	539K	343K	114.0	108.3
Net Income Applicable To Common Shares	(1.0M)	(1.2M)	(1.4M)	(986K)	(1.1M)	(1.2M)
Net Interest Income	5K	(6K)	(11K)	4K	3.6K	3.8K
Reconciled Depreciation	56K	100K	57K	25K	2K	0.0

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Vaxil Stock Analysis

When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vaxil Historical Income Statement

About Vaxil Income Statement Analysis

Vaxil Bio Income Statement Chart

Other Operating Expenses

Cost Of Revenue

Income Before Tax

Net Income

Vaxil Bio income statement Correlations

Vaxil Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vaxil Bio income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Vaxil Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Ebitda

Ebit	- 1.0	Total Operating Expenses
Net Income	- 1.0	Total Operating Expenses
Income Before Tax	- 1.0	Total Operating Expenses
Total Operating Expenses	- 1.0	Ebitda
Total Operating Expenses	- 1.0	Operating Income
Ebit	- 1.0	Other Operating Expenses